This producer of small heart pumps hasn’t missed a beat as the FDA approved Impella 2.5, a version of its flagship device for high-risk patients.
Company Information
Location | Danvers, MA |
Industry | Medical Products & Equipment |
Sector | Health Care |
Fortune 500 Rank | - |
Fortune 500 Profile | - |
Current Streak | 1 |
Years on List | 1 |
CEO | Michael R. Minogue |
Website | http://www.abiomed.com |
Revenue, Net Income
Revenue Past Four Quarters | 230 |
Net Income Past Four Quarters | 114 |
Growth Rates
EPS 3 yr Annual Growth Rate | 65% |
Rev 3 yr Annual Growth Rate | 20% |
Total Return 3 yr Annual Rate | 42% |
Beat S&P 3 yr Total Return? | yes |
Rank
EPS Growth Rank | 34 |
Revenue Growth Rank | 87 |
Total Return Rank | 50 |